Henlius Entered into an Exclusive License Agreement with Fosun Pharma for HANSIZHUANG in the US
- Henlius will receive $143.39M up front & milestones along with royalties. Fosun to get the right to commercialize Henlius’ HANSIZHUANG (anti-PD-1 mAb) in the US by using its capabilities & provides the patients' benefits globally while Henlius will lead the development, manufacturing & supply
- The companies focus to develop HANSIZHUANG, integrating superior resources & promoting the US launch. The companies collaborated on product commercialization & other areas, understanding corporate vision & values, development strategy, product operations & management communication, focusing on patients’ & clinical needs
- The international medical journal published HANSIZHUANG’s clinical data. The product was approved in China for MSI-H solid tumors & sq.NSCLC; ODD for SCLC in the US & EC
Ref: Globenewswire | Image: Nanobiotix
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.